Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
AXGN 
Axogen Inc (AXGN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/01/2025: AXGN (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
7 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $24.29
1 Year Target Price $24.29
| 5 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 50.25% | Avg. Invested days 36 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 07/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 494.15M USD | Price to earnings Ratio - | 1Y Target Price 24.29 |
Price to earnings Ratio - | 1Y Target Price 24.29 | ||
Volume (30-day avg) 7 | Beta 1.06 | 52 Weeks Range 7.23 - 21.00 | Updated Date 07/1/2025 |
52 Weeks Range 7.23 - 21.00 | Updated Date 07/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.16 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -3.68% | Operating Margin (TTM) -3.42% |
Management Effectiveness
Return on Assets (TTM) -0.13% | Return on Equity (TTM) -7.22% |
Valuation
Trailing PE - | Forward PE 40.16 | Enterprise Value 540526877 | Price to Sales(TTM) 2.54 |
Enterprise Value 540526877 | Price to Sales(TTM) 2.54 | ||
Enterprise Value to Revenue 2.78 | Enterprise Value to EBITDA 61.5 | Shares Outstanding 45544000 | Shares Floating 44743380 |
Shares Outstanding 45544000 | Shares Floating 44743380 | ||
Percent Insiders 4.84 | Percent Institutions 86.2 |
Analyst Ratings
Rating 2 | Target Price 24.29 | Buy 2 | Strong Buy 5 |
Buy 2 | Strong Buy 5 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Axogen Inc
Company Overview
History and Background
Axogen Inc. was founded in 2002. It focuses on developing and marketing innovative solutions for peripheral nerve repair. Initially a research-focused company, it has grown into a commercial organization with a portfolio of nerve repair products.
Core Business Areas
- Nerve Repair and Regeneration: Axogen's core business revolves around providing products and services for the surgical repair of peripheral nerves. This includes products for nerve allograft, nerve protection, and nerve stimulation.
Leadership and Structure
Axogen Inc. is led by a management team with expertise in medical devices and biotechnology. The organizational structure includes departments for research and development, sales and marketing, manufacturing, and regulatory affairs.
Top Products and Market Share
Key Offerings
- Avance Nerve Graft: Avance Nerve Graft is a processed nerve allograft used for bridging nerve gaps. It holds a significant share in the nerve repair market. Exact market share data is proprietary but is a market leader. Competitors include Integra LifeSciences (IART).
- AxoGuard Nerve Connector: AxoGuard Nerve Connector is a porcine submucosa extracellular matrix (ECM) scaffold used to protect and repair injured peripheral nerves. It competes with products from Stryker (SYK) and Medtronic (MDT).
- AxoTouch Nerve Protector: AxoTouch is a nerve protector product used for various surgical indications, offering protection to nerve tissues. The competitors include Integra LifeSciences (IART).
Market Dynamics
Industry Overview
The peripheral nerve repair market is growing due to increasing incidence of traumatic injuries, surgical procedures and improved awareness of nerve damage treatment options.
Positioning
Axogen is a key player in the peripheral nerve repair market, with a focus on providing innovative solutions for nerve regeneration and repair. They are seen as a market leader in nerve allografts.
Total Addressable Market (TAM)
Estimated TAM for nerve repair is in the billions of USD annually. Axogen is positioned to capture a significant portion of this market through their product portfolio.
Upturn SWOT Analysis
Strengths
- Proprietary nerve repair technologies
- Established market presence
- Strong relationships with surgeons
- Focus on nerve regeneration
Weaknesses
- Reliance on a limited number of products
- Regulatory risks associated with biologics
- High cost of goods sold
- Dependence on hospital purchasing decisions
Opportunities
- Expansion into new geographic markets
- Development of new nerve repair products
- Partnerships with other medical device companies
- Increasing awareness of nerve repair treatments
Threats
- Competition from established medical device companies
- Reimbursement pressures from healthcare providers
- Potential for product liability claims
- Changes in regulatory requirements
Competitors and Market Share
Key Competitors
- Integra LifeSciences (IART)
- Stryker (SYK)
- Medtronic (MDT)
Competitive Landscape
Axogen's advantage lies in its specialized focus on nerve repair. It faces competition from larger, more diversified medical device companies.
Growth Trajectory and Initiatives
Historical Growth: Axogen has experienced revenue growth in past years, driven by increased adoption of its nerve repair products.
Future Projections: Analyst estimates suggest continued growth for Axogen, driven by increasing demand for nerve repair solutions.
Recent Initiatives: Axogen has been focused on expanding its product portfolio and geographic reach.
Summary
Axogen is a key player in the nerve repair market, with proprietary technology and a focus on nerve regeneration. While it benefits from established market presence, reliance on a limited number of products and regulatory risks are challenges. Future growth relies on market expansion and developing new nerve repair products, competing effectively against larger players. They need to focus on reducing costs and ensuring regulatory compliance.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Analyst reports
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. Market share data is an approximation. Please consult with a financial advisor before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Axogen Inc
Exchange NASDAQ | Headquaters Alachua, FL, United States | ||
IPO Launch date 1990-03-27 | President, CEO & Director Mr. Michael D. Dale | ||
Sector Healthcare | Industry Medical Devices | Full time employees 451 | Website https://www.axogeninc.com |
Full time employees 451 | Website https://www.axogeninc.com | ||
Axogen, Inc., together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma. The company provides its products to hospitals, surgery centers, and military hospitals, plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons. Axogen, Inc. is headquartered in Alachua, Florida.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.